Healthcare Providers

INTERESTED IN YOUR INSTITUTION BEING A PART OF THIS HISTORIC TRIAL?

Any institution within the National Cancer Institute's National Clinical Trials Network (NCTN) may open the Lung-MAP study at their site.  Learn more about the protocol at clinicaltrials.gov or by contacting the Lung-MAP protocol coordinator:

Crystal Miwa
cmiwa@swog.org
(210) 614-8808 Ext 1019

Looking for the study protocol and other resources for institutions opening Lung-MAP?  You can find them at: SWOG members protocol abstract page or CTSU website members section

Some aspects of the trial have undergone revision. A summary of the changes is available here.

What are the main objectives of Lung-MAP?

The primary objective of each Lung-MAP trial sub-study is to learn whether a targeted cancer therapy that is matched to the genomic makeup of a patient’s lung cancer tumor is more effective than the current standard therapy in halting or reversing the progress of the disease and in extending the patient’s life.

A key part of the Lung-MAP trial is that it will screen a large population of patient volunteers with squamous cell lung cancer and evaluate the genetic characteristics of their tumors.  Based on these results, each patient will be assigned to the trial sub-study testing an investigational drug that is best matched to their tumor’s genomic profile.

What are Lung-MAP’s secondary objectives?

Researchers on each trial sub-study will also compare the tumor response rates and the frequency and severity of side effects patients experience on the targeted-therapy arm versus the standard-of-care arm.

The National Cancer Institute will store tumor and blood samples from patients enrolled in the trial for future exploratory research on squamous cell lung cancer.

What are the benefits of the Lung-MAP approach to cancer research?

  • Enrollment efficiency:  A single test that looks at >200 cancer-related genes for genomic alterations that will help match patients to multiple trial sub-studies is more efficient than a separate screening process for each trial.
  • Operational efficiency:  A single “master protocol” can be amended as needed as drugs enter and exit the trial, rather than developing and launching a separate protocol for each new drug.
  • Predictability:  If a drug meets predetermined efficacy and safety criteria, the drug and its accompanying diagnostic biomarker will be eligible for FDA approval.

Who is conducting the Lung-MAP trial?

The trial will open at a network of cancer centers, community hospitals, academic medical centers, and physician cooperatives across the United States with operations being managed by SWOG Cancer Research within the National Cancer Institute’s National Clinical Trials Network. 

How many patients will take part in Lung-MAP?

Lung-MAP is designed to enroll from 500 to 1,000 patients each year.  This number may increase as more trial sub-studies are added to the Lung-MAP protocol. 

Where can I learn more about Lung-MAP?

As more detailed information about the trial becomes available, it will be summarized on this website.  Detailed information is also available here: https://clinicaltrials.gov/ct2/show/NCT02154490

 

 

Genomic profile screening

Patients are screened using a comprehensive genomic profiling platform that looks at over 200 cancer-related genes for genomic alterations.

 

Sub-study Assignment

Based on the results of this screening, patients are assigned to whichever one of up to five sub-studies testing different investigational treatments best suits their genomic profile.

 

Innovative Approach

This innovative approach improves a patient’s likelihood of receiving a drug targeted at the genetic profile of their particular tumor while allowing for new therapies in development to be added as the trial progresses.